No retraction, correction or concern found when last checked on Oct 21, 2026.

Prevalence and predictors of death and severe disease in patients hospitalized due to COVID-19: A comprehensive systematic review and meta-analysis of 77 studies and 38,000 patients

Kunchok Dorjee, Hyunju Kim, Elizabeth Bonomo and 1 more

PLOS ONE · 2020 · Meta-analysis · CC BY

doi:10.1371/journal.pone.0243191

Abstract

Introduction. Progression of COVID-19 to severe disease and death is insufficiently understood.

Objective. Summarize the prevalence of risk factors and adverse outcomes and determine their associations in COVID-19 patients who were hospitalized.

Methods. We searched Medline, Embase and Web of Science for case-series and observational studies of hospitalized COVID-19 patients through August 31, 2020. Data were analyzed by fixed-effects meta-analysis using Shore’s adjusted confidence intervals to address heterogeneity.

Results. Seventy-seven studies comprising 38906 hospitalized patients met inclusion criteria; 21468 from the US-Europe and 9740 from China. Overall prevalence of death [% (95% CI)] from COVID-19 was 20% (18–23%); 23% (19–27%) in the US and Europe and 11% (7–16%) for China. Of those that died, 85% were aged≥60 years, 66% were males, and 66%, 44%, 39%, 37%, and 27% had hypertension, smoking history, diabetes, heart disease, and chronic kidney disease (CKD), respectively. The case fatality risk [%(95% CI)] were 52% (46–60) for heart disease, 51% (43–59) for COPD, 48% (37–63) for chronic kidney disease (CKD), 39% for chronic liver disease (CLD), 28% (23–36%) for hypertension, and 24% (17–33%) for diabetes. Summary relative risk (sRR) of death were higher for age≥60 years [sRR = 3.6; 95% CI: 3.0–4.4], males [1.3; 1.2–1.4], smoking history [1.3; 1.1–1.6], COPD [1.7; 1.4–2.0], hypertension [1.8; 1.6–2.0], diabetes [1.5; 1.4–1.7], heart disease [2.1; 1.8–2.4], CKD [2.5; 2.1–3.0]. The prevalence of hypertension (55%), diabetes (33%), smoking history (23%) and heart disease (17%) among the COVID-19 hospitalized patients in the US were substantially higher than that of the general US population, suggesting increased susceptibility to infection or disease progression for the individuals with comorbidities.

Conclusions. Public health screening for COVID-19 can be prioritized based on risk-groups. Appropriately addressing the modifiable risk factors such as smoking, hypertension, and diabetes could reduce morbidity and mortality due to COVID-19; public messaging can be accordingly adapted.

References 121

1.
Johns Hopkins University. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). https://coronavirus.jhu.edu/map.html. Published 2020. Accessed October 8, 2020.
Not in our library
2.
Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 — COVID-NET, 14 States, March 1–30, 2020 · 2020
No notice
3.
Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020:
Not in our library10.1001/jama.2020.2648
4.
Cummings MJ, Baldwin MR, Abrams D, et al Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. 2020;395(10239):1763–1770.
Not in our library10.1016/s0140-6736(20)31189-2
5.
Du RH, Liang LR, Yang CQ, et al Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J. 2020;55(5).
Not in our library10.1183/13993003.00524-2020
6.
Li X, Xu S, Yu M, et al Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146(1):110–118.
Not in our library10.1016/j.jaci.2020.04.006
7.
Palaiodimos L, Kokkinidis DG, Li W, et al Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a cohort of patients with COVID-19 in the Bronx, New York. Metabolism. 2020;108:154262
Not in our library10.1016/j.metabol.2020.154262
8.
Wu C, Chen X, Cai Y, et al Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934–943.
Not in our library10.1001/jamainternmed.2020.0994
9.
Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis · 2020
No notice
10.
Lippi G, Henry BM. Active smoking is not associated with severity of coronavirus disease 2019 (COVID-19). Eur J Intern Med. 2020;75:107–108.
Not in our library10.1016/j.ejim.2020.03.014
11.
Patanavanich R, Glantz SA. Smoking Is Associated With COVID-19 Progression: A Meta-analysis. Nicotine Tob Res. 2020;22(9):1653–1656.
Not in our library10.1093/ntr/ntaa082
12.
Rossato M, Russo L, Mazzocut S, Di Vincenzo A, Fioretto P, Vettor R. Current smoking is not associated with COVID-19. Eur Respir J. 2020;55(6).
Not in our library10.1183/13993003.01290-2020
13.
Guan WJ, Liang WH, Zhao Y, et al Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55(5).
Not in our library10.1183/13993003.00547-2020
14.
Zhou F, Yu T, Du R, et al Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062.
Not in our library10.1016/s0140-6736(20)30566-3
15.
Akhmerov A, Marban E. COVID-19 and the Heart. Circ Res. 2020;126(10):1443–1455.
Not in our library10.1161/circresaha.120.317055
16.
Schiffrin EL, Flack JM, Ito S, Muntner P, Webb RC. Hypertension and COVID-19. Am J Hypertens. 2020;33(5):373–374.
Not in our library10.1093/ajh/hpaa057
17.
Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17(5):259–260.
Not in our library10.1038/s41569-020-0360-5
18.
Li X, Guan B, Su T, et al Impact of cardiovascular disease and cardiac injury on in-hospital mortality in patients with COVID-19: a systematic review and meta-analysis. Heart. 2020;106(15):1142–1147.
Not in our library10.1136/heartjnl-2020-317062
19.
Yang J, Zheng Y, Gou X, et al Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91–95.
Not in our library10.1016/j.ijid.2020.03.017
20.
Zheng Z, Peng F, Xu B, et al Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect. 2020;81(2):e16–e25.
Not in our library10.1016/j.jinf.2020.04.021
21.
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–188.
Not in our library10.1016/0197-2456(86)90046-2
22.
Cochran WG. The Combination of Estimates From Different Experiments. Biometrics. 1954;10(1):101–129.
Not in our library
23.
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–1558.
Not in our library10.1002/sim.1186
24.
Shore RE, Gardner MJ, Pannett B. Ethylene oxide: an assessment of the epidemiological evidence on carcinogenicity. Br J Ind Med. 1993;50(11):971–997.
Not in our library10.1136/oem.50.11.971
25.
Aggarwal S, Garcia-Telles N, Aggarwal G, Lavie C, Lippi G, Henry BM. Clinical features, laboratory characteristics, and outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19): Early report from the United States. Diagnosis. 2020;7(2):91–96.
Not in our library10.1515/dx-2020-0046
26.
Argenziano MG, Bruce SL, Slater CL, et al Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series. Bmj. 2020;369:m1996
Not in our library10.1136/bmj.m1996
27.
Brill SE, Jarvis HC, Ozcan E, et al COVID-19: a retrospective cohort study with focus on the over-80s and hospital-onset disease. BMC Med. 2020;18(1):194
Not in our library10.1186/s12916-020-01665-z
28.
Cao Z, Li T, Liang L, et al Clinical characteristics of Coronavirus Disease 2019 patients in Beijing, China. PLoS One. 2020;15(6):e0234764
Not in our library10.1371/journal.pone.0234764
29.
Chen G, Wu D, Guo W, et al Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620–2629.
Not in our library10.1172/jci137244
30.
Chen J, Qi T, Liu L, et al Clinical progression of patients with COVID-19 in Shanghai, China. J Infect. 2020;80(5):e1–e6.
Not in our library10.1016/j.jinf.2020.03.004
31.
Clinical characteristics of 145 patients with corona virus disease 2019 (COVID-19) in Taizhou, Zhejiang, China · 2020
No notice
32.
Chen T, Wu D, Chen H, et al Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368:m1091–m1091.
Not in our library10.1136/bmj.m1091
33.
Chilimuri S, Sun H, Alemam A, et al Predictors of Mortality in Adults Admitted with COVID-19: Retrospective Cohort Study from New York City. West J Emerg Med. 2020;21(4):779–784.
Not in our library10.5811/westjem.2020.6.47919
34.
Ciceri F, Castagna A, Rovere-Querini P, et al Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy. Clin Immunol. 2020;217:108509
Not in our library10.1016/j.clim.2020.108509
35.
Deng Y, Liu W, Liu K, et al Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study. Chin Med J (Engl). 2020;133(11):1261–1267.
Not in our library10.1097/cm9.0000000000000824
36.
Escalera-Antezana JP, Lizon-Ferrufino NF, Maldonado-Alanoca A, et al Risk factors for mortality in patients with Coronavirus Disease 2019 (COVID-19) in Bolivia: An analysis of the first 107 confirmed cases. Infez Med. 2020;28(2):238–242.
Not in our library
37.
Feng Y, Ling Y, Bai T, et al COVID-19 with Different Severities: A Multicenter Study of Clinical Features. Am J Respir Crit Care Med. 2020;201(11):1380–1388.
Not in our library10.1164/rccm.202002-0445oc
38.
Ferguson J, Rosser JI, Quintero O, et al Characteristics and Outcomes of Coronavirus Disease Patients under Nonsurge Conditions, Northern California, USA, March-April 2020. Emerg Infect Dis. 2020;26(8).
Not in our library10.3201/eid2608.201776
39.
Galloway JB, Norton S, Barker RD, et al A clinical risk score to identify patients with COVID-19 at high risk of critical care admission or death: An observational cohort study. J Infect. 2020;81(2):282–288.
Not in our library10.1016/j.jinf.2020.05.064
40.
Garibaldi BT, Fiksel J, Muschelli J, et al Patient Trajectories Among Persons Hospitalized for COVID-19: A Cohort Study. Ann Intern Med. 2020
Not in our library10.7326/m20-3905
41.
Giacomelli A, Ridolfo AL, Milazzo L, et al 30-day mortality in patients hospitalized with COVID-19 during the first wave of the Italian epidemic: A prospective cohort study. Pharmacol Res. 2020;158:104931
Not in our library10.1016/j.phrs.2020.104931
42.
Characteristics and Clinical Outcomes of Adult Patients Hospitalized with COVID-19 — Georgia, March 2020 · 2020
No notice
43.
Goyal P, Choi JJ, Pinheiro LC, et al Clinical Characteristics of Covid-19 in New York City. N Engl J Med. 2020;382(24):2372–2374.
Not in our library10.1056/nejmc2010419
44.
Gregoriano C, Koch D, Haubitz S, et al Characteristics, predictors and outcomes among 99 patients hospitalised with COVID-19 in a tertiary care centre in Switzerland: an observational analysis. Swiss Med Wkly. 2020;150:w20316
Not in our library10.4414/smw.2020.20316
45.
Guan WJ, Ni ZY, Hu Y, et al Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720.
Not in our library10.1056/nejmoa2002032
46.
The effect of frailty on survival in patients with COVID-19 (COPE): a multicentre, European, observational cohort study · 2020
No notice
47.
Race/Ethnicity, Underlying Medical Conditions, Homelessness, and Hospitalization Status of Adult Patients with COVID-19 at an Urban Safety-Net Medical Center — Boston, Massachusetts, 2020 · 2020
No notice
48.
Hu L, Chen S, Fu Y, et al Risk Factors Associated with Clinical Outcomes in 323 COVID-19 Hospitalized Patients in Wuhan, China. Clin Infect Dis. 2020
Not in our library10.1093/cid/ciaa539
49.
Huang C, Wang Y, Li X, et al Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
Not in our library10.1016/s0140-6736(20)30183-5
50.
Factors Associated With Intubation and Prolonged Intubation in Hospitalized Patients With COVID‐19 · 2020
Corrected
51.
Iaccarino G, Grassi G, Borghi C, Ferri C, Salvetti M, Volpe M. Age and Multimorbidity Predict Death Among COVID-19 Patients: Results of the SARS-RAS Study of the Italian Society of Hypertension. Hypertension. 2020;76(2):366–372.
Not in our library10.1161/hypertensionaha.120.15324
52.
Inciardi RM, Adamo M, Lupi L, et al Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy. Eur Heart J. 2020;41(19):1821–1829.
Not in our library10.1093/eurheartj/ehaa388
53.
Jang JG, Hur J, Choi EY, Hong KS, Lee W, Ahn JH. Prognostic Factors for Severe Coronavirus Disease 2019 in Daegu, Korea. J Korean Med Sci. 2020;35(23):e209
Not in our library10.3346/jkms.2020.35.e209
54.
Javanian M, Bayani M, Shokri M, et al Clinical and laboratory findings from patients with COVID-19 pneumonia in Babol North of Iran: a retrospective cohort study. Rom J Intern Med. 2020;58(3):161–167.
Not in our library10.2478/rjim-2020-0013
55.
Kalligeros M, Shehadeh F, Mylona EK, et al Association of Obesity with Disease Severity Among Patients with Coronavirus Disease 2019. Obesity (Silver Spring). 2020;28(7):1200–1204.
Not in our library10.1002/oby.22859
56.
Khalil K, Agbontaen K, McNally D, et al Clinical characteristics and 28-day mortality of medical patients admitted with COVID-19 to a central London teaching hospital. J Infect. 2020;81(3):e85–e89.
Not in our library10.1016/j.jinf.2020.06.027
57.
Khamis F, Al-Zakwani I, Al Naamani H, et al Clinical characteristics and outcomes of the first 63 adult patients hospitalized with COVID-19: An experience from Oman. J Infect Public Health. 2020;13(7):906–913.
Not in our library10.1016/j.jiph.2020.06.002
58.
Lendorf ME, Boisen MK, Kristensen PL, et al Characteristics and early outcomes of patients hospitalised for COVID-19 in North Zealand, Denmark. Dan Med J. 2020;67(9).
Not in our library
59.
Liu S, Luo H, Wang Y, et al Clinical characteristics and risk factors of patients with severe COVID-19 in Jiangsu province, China: a retrospective multicentre cohort study. BMC Infect Dis. 2020;20(1):584
Not in our library10.1186/s12879-020-05314-x
60.
Liu W, Tao ZW, Wang L, et al Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med J (Engl). 2020;133(9):1032–1038.
Not in our library10.1097/cm9.0000000000000775
61.
Nikpouraghdam M, Jalali Farahani A, Alishiri G, et al Epidemiological characteristics of coronavirus disease 2019 (COVID-19) patients in IRAN: A single center study. J Clin Virol. 2020;127:104378
Not in our library10.1016/j.jcv.2020.104378
62.
Nowak B, Szymanski P, Pankowski I, et al Clinical characteristics and short-term outcomes of patients with coronavirus disease 2019: a retrospective single-center experience of a designated hospital in Poland. Pol Arch Intern Med. 2020;130(5):407–411.
Not in our library10.20452/pamw.15361
63.
Coronavirus disease 19 in minority populations of Newark, New Jersey · 2020
Not checked
64.
Pellaud C, Grandmaison G, Pham Huu Thien HP, et al Characteristics, comorbidities, 30-day outcome and in-hospital mortality of patients hospitalised with COVID-19 in a Swiss area—a retrospective cohort study. Swiss Med Wkly. 2020;150:w20314
Not in our library10.4414/smw.2020.20314
65.
Richardson S, Hirsch JS, Narasimhan M, et al Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020;323(20):2052–2059.
Not in our library10.1001/jama.2020.6775
66.
Rivera-Izquierdo M, Del Carmen Valero-Ubierna M, JL Rd, et al Sociodemographic, clinical and laboratory factors on admission associated with COVID-19 mortality in hospitalized patients: A retrospective observational study. PLoS One. 2020;15(6):e0235107
Not in our library10.1371/journal.pone.0235107
67.
Shabrawishi M, Al-Gethamy MM, Naser AY, et al Clinical, radiological and therapeutic characteristics of patients with COVID-19 in Saudi Arabia. PLoS One. 2020;15(8):e0237130
Not in our library10.1371/journal.pone.0237130
68.
Epidemiological and clinical features of 2019 novel coronavirus diseases (COVID-19) in the South of Iran · 2020
Not checked
69.
Shekhar R, Sheikh AB, Upadhyay S, Atencio J, Kapuria D. Early experience with COVID-19 patients at academic hospital in Southwestern United States. Infect Dis (Lond). 2020;52(8):596–599.
Not in our library10.1080/23744235.2020.1774645
70.
Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan · 2020
No notice
71.
Clinical Characteristics and Morbidity Associated With Coronavirus Disease 2019 in a Series of Patients in Metropolitan Detroit · 2020
No notice
72.
Sun L, Shen L, Fan J, et al Clinical features of patients with coronavirus disease 2019 from a designated hospital in Beijing, China. J Med Virol. 2020
Not in our library10.1002/jmv.25966
73.
An epidemiological study of laboratory confirmed COVID-19 cases admitted in a tertiary care hospital of Pune, Maharashtra · 2020
Not checked
74.
Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 — United States, February 12–March 28, 2020 · 2020
No notice
75.
Tian S, Hu N, Lou J, et al Characteristics of COVID-19 infection in Beijing. J Infect. 2020;80(4):401–406.
Not in our library10.1016/j.jinf.2020.02.018
76.
Tomlins J, Hamilton F, Gunning S, Sheehy C, Moran E, MacGowan A. Clinical features of 95 sequential hospitalised patients with novel coronavirus 2019 disease (COVID-19), the first UK cohort. J Infect. 2020;81(2):e59–e61.
Not in our library10.1016/j.jinf.2020.04.020
77.
Turcotte JJ, Meisenberg BR, MacDonald JH, et al Risk factors for severe illness in hospitalized Covid-19 patients at a regional hospital. PLoS One. 2020;15(8):e0237558
Not in our library10.1371/journal.pone.0237558
78.
Wan S, Xiang Y, Fang W, et al Clinical features and treatment of COVID-19 patients in northeast Chongqing. J Med Virol. 2020;92(7):797–806.
Not in our library10.1002/jmv.25783
79.
Wang D, Hu B, Hu C, et al Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020:
Not in our library10.1001/jama.2020.1585
80.
Epidemiological and clinical features of 125 Hospitalized Patients with COVID-19 in Fuyang, Anhui, China · 2020
Not checked
81.
Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical Features of 69 Cases With Coronavirus Disease 2019 in Wuhan, China. Clin Infect Dis. 2020;71(15):769–777.
Not in our library10.1093/cid/ciaa272
82.
Wei Y, Zeng W, Huang X, et al Clinical characteristics of 276 hospitalized patients with coronavirus disease 2019 in Zengdu District, Hubei Province: a single-center descriptive study. BMC Infect Dis. 2020;20(1):549
Not in our library10.1186/s12879-020-05252-8
83.
Yang X, Yu Y, Xu J, et al Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475–481.
Not in our library10.1016/s2213-2600(20)30079-5
84.
Yao Q, Wang P, Wang X, et al A retrospective study of risk factors for severe acute respiratory syndrome coronavirus 2 infections in hospitalized adult patients. Pol Arch Intern Med. 2020;130(5):390–399.
Not in our library10.20452/pamw.15312
85.
Young BE, Ong SWX, Kalimuddin S, et al Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. JAMA. 2020;323(15):1488–1494.
Not in our library10.1001/jama.2020.3204
86.
Yu T, Cai S, Zheng Z, et al Association Between Clinical Manifestations and Prognosis in Patients with COVID-19. Clin Ther. 2020;42(6):964–972.
Not in our library10.1016/j.clinthera.2020.04.009
87.
Yu X, Sun X, Cui P, et al Epidemiological and clinical characteristics of 333 confirmed cases with coronavirus disease 2019 in Shanghai, China. Transbound Emerg Dis. 2020;67(4):1697–1707.
Not in our library10.1111/tbed.13604
88.
Zhan T, Liu M, Tang Y, et al Retrospective analysis of clinical characteristics of 405 patients with COVID-19. J Int Med Res. 2020;48(8):300060520949039
Not in our library10.1177/0300060520949039
89.
Analysis of clinical characteristics and laboratory findings of 95 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a retrospective analysis · 2020
No notice
90.
Zhang J, Wang X, Jia X, et al Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China. Clin Microbiol Infect. 2020;26(6):767–772.
Not in our library10.1016/j.cmi.2020.04.012
91.
Zhang J-J, Dong X, Cao Y-Y, et al Clinical characteristics of 140 patients infected by SARS-CoV-2 in Wuhan, China. Allergy. 2020:
Not in our library10.1111/all.14238
92.
Clinical characteristics of patients with 2019 coronavirus disease in a non-Wuhan area of Hubei Province, China: a retrospective study · 2020
No notice
93.
Zheng S, Fan J, Yu F, et al Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study. BMJ. 2020;369:m1443
Not in our library10.1136/bmj.m1443
94.
Zheng Y, Xiong C, Liu Y, et al Epidemiological and Clinical Characteristics Analysis of COVID-19 in the Surrounding Areas of Wuhan, Hubei Province in 2020. Pharmacological Research. 2020:104821
Not in our library10.1016/j.phrs.2020.104821
95.
Qin A. China Raises Coronavirus Death Toll by 50% in Wuhan. The New York Times. 4 17, 2020, 2020.
Not in our library
96.
National Smoking Rates Correlate Inversely with COVID-19 Mortality. 2020. https://www.medrxiv.org/content/10.1101/2020.06.12.20129825v1. Accessed Oct 6, 2020.
Not in our library
97.
Factors associated with COVID-19-related death using OpenSAFELY · 2020
No notice
98.
Zhao Q, Meng M, Kumar R, et al The impact of COPD and smoking history on the severity of COVID-19: A systemic review and meta-analysis. J Med Virol. 2020
Not in our library10.1002/jmv.25889
99.
Cai G, Bosse Y, Xiao F, Kheradmand F, Amos CI. Tobacco Smoking Increases the Lung Gene Expression of ACE2, the Receptor of SARS-CoV-2. Am J Respir Crit Care Med. 2020;201(12):1557–1559.
Not in our library10.1164/rccm.202003-0693le
100.
Clerkin KJ, Fried JA, Raikhelkar J, et al COVID-19 and Cardiovascular Disease. Circulation. 2020;141(20):1648–1655.
Not in our library10.1161/circulationaha.120.046941
101.
South AM, Diz DI, Chappell MC. COVID-19, ACE2, and the cardiovascular consequences. Am J Physiol Heart Circ Physiol. 2020;318(5):H1084–H1090.
Not in our library10.1152/ajpheart.00217.2020
102.
Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8(4):e21
Not in our library10.1016/s2213-2600(20)30116-8
103.
Hoffmann M, Kleine-Weber H, Schroeder S, et al SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell.
Not in our library10.1016/j.cell.2020.02.052
104.
Li W, Moore MJ, Vasilieva N, et al Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450–454.
Not in our library10.1038/nature02145
105.
Pan W, Zhang J, Wang M, et al Clinical Features of COVID-19 in Patients With Essential Hypertension and the Impacts of Renin-angiotensin-aldosterone System Inhibitors on the Prognosis of COVID-19 Patients. Hypertension. 2020;76(3):732–741.
Not in our library10.1161/hypertensionaha.120.15289
106.
Zhu L, She ZG, Cheng X, et al Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metab. 2020;31(6):1068–1077 e1063.
Not in our library10.1016/j.cmet.2020.04.021
107.
Kreutz R, Algharably EAE, Azizi M, et al Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19. Cardiovasc Res. 2020;116(10):1688–1699.
Not in our library10.1093/cvr/cvaa097
108.
Radzikowska U, Ding M, Tan G, et al Distribution of ACE2, CD147, CD26, and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors. Allergy. 2020.
Not in our library10.1111/all.14429
109.
Pinto BGG, Oliveira AER, Singh Y, et al ACE2 Expression Is Increased in the Lungs of Patients With Comorbidities Associated With Severe COVID-19. J Infect Dis. 2020;222(4):556–563.
Not in our library10.1093/infdis/jiaa332
110.
Tobacco Product Use and Cessation Indicators Among Adults — United States, 2018 · 2019
No notice
111.
Fryar CD, Ostchega Y, Hales CM, Zhang G, Kruszon-Moran D. Hypertension Prevalence and Control Among Adults: United States, 2015–2016. NCHS Data Brief. 2017 (289):1–8.
Not in our library
112.
United States Centers for Disease Control and Prevention. National Diabetes Statistics Report. Atlanta, GA 2020.
Not in our library
113.
Benjamin EJ, Muntner P, Alonso A, et al Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation. 2019;139(10):e56–e528.
Not in our library10.1161/cir.0000000000000659
114.
Biener AI, Decker SL, Rohde F. Prevalence and Treatment of Chronic Obstructive Pulmonary Disease (COPD) in the United States. JAMA. 2019;322(7):602
Not in our library10.1001/jama.2019.10241
115.
United States Centers for Disease Control and Prevention. Chronic Kidney Disease in the United States, 2019 https://www.cdc.gov/kidneydisease/pdf/2019_National-Chronic-Kidney-Disease-Fact-Sheet.pdf. Published 2019. Accessed June 7, 2020, 2020.
Not in our library
116.
Wang Z, Chen Z, Zhang L, et al Status of Hypertension in China: Results From the China Hypertension Survey, 2012–2015. Circulation. 2018;137(22):2344–2356.
Not in our library10.1161/circulationaha.117.032380
117.
Hu C, Jia W. Diabetes in China: Epidemiology and Genetic Risk Factors and Their Clinical Utility in Personalized Medication. Diabetes. 2018;67(1):3–11.
Not in our library10.2337/dbi17-0013
118.
Wang M, Luo X, Xu S, et al Trends in smoking prevalence and implication for chronic diseases in China: serial national cross-sectional surveys from 2003 to 2013. Lancet Respir Med. 2019;7(1):35–45.
Not in our library10.1016/s2213-2600(18)30432-6
119.
Ma LY, Chen WW, Gao RL, et al China cardiovascular diseases report 2018: an updated summary. J Geriatr Cardiol. 2020;17(1):1–8.
Not in our library10.11909/j.issn.1671-5411.2020.01.001
120.
Fang L, Gao P, Bao H, et al Chronic obstructive pulmonary disease in China: a nationwide prevalence study. Lancet Respir Med. 2018;6(6):421–430.
Not in our library10.1016/s2213-2600(18)30103-6
121.
Zhang L, Wang F, Wang L, et al Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet. 2012;379(9818):815–822.
Not in our library10.1016/s0140-6736(12)60033-6

Cited by papers we hold 1

Pre-existing health conditions and severe COVID-19 outcomes: an umbrella review approach and meta-analysis of global evidence · 2021
No notice

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.